Basis: Unrounded diluted TTM EPS / FMP quote price × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The earnings yield is N/A as of 2026-10-06T21:57:09.556Z.
Calculation as of: 2026-10-06T21:57:09.556Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b6dd554127bde3e2857ddd2c1d40451f36e78030673a0e1a1dc90bdbe20c6bc6
EARNINGS YIELD
N/A
Market Cap
$3.54B
Earnings Yield
N/A
TTM Avg
3.23%
3Y Avg
3.30%
5Y Avg
3.30%
Market Cap
$3.64B
Earnings Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.38B
Earnings Yield
11.25%
TTM Avg
8.17%
3Y Avg
6.43%
5Y Avg
6.43%
| NAME | MARKET CAP | EARNINGS YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| iRhythm Technologies, Inc. (IRTC) | $3.52B | N/A | N/A | N/A | N/A |
| Xenon Pharmaceuticals Inc. (XENE)vs › | $3.54B | N/A | 3.23% | 3.30% | 3.30% |
| Veracyte, Inc. (VCYT)vs › | $3.56B | 3.14% | 1.91% | 1.65% | 1.65% |
| IDEAYA Biosciences, Inc. (IDYA)vs › | $3.48B | N/A | N/A | N/A | N/A |
| Tango Therapeutics, Inc. (TNGX)vs › | $3.57B | N/A | N/A | N/A | N/A |
| Celcuity Inc. (CELC)vs › | $3.47B | N/A | N/A | N/A | N/A |
| Pulse Biosciences, Inc. (PLSE)vs › | $3.44B | N/A | N/A | N/A | N/A |
| Regencell Bioscience Holdings Limited (RGC)vs › | $3.64B | N/A | N/A | N/A | N/A |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.38B | 11.25% | 8.17% | 6.43% | 6.43% |
| Parabilis Medicines, Inc. (PBLS)vs › | $3.36B | N/A | N/A | N/A | N/A |
Earnings Yield
N/A
EPS ÷ Price
P/E Ratio
N/A
Price ÷ EPS
Formula: Earnings Yield = (EPS / Price) × 100
Earnings Yield is simply the inverse of P/E. A P/E of 20 equals a 5% earnings yield.
How earnings yield is used:
Earnings Yield = EPS (TTM) / Share Price
Earnings yield is the inverse of the PE ratio, expressing trailing earnings as a percentage of price. Higher is cheaper.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
